Keywords: cytochroma, selects, psoriasis, drug, candidate, canada, selected
Cytochroma selects psoriasis drug candidate
Article | 29 September 2003
Canada's Cytochroma has selected CTA018 as a drug candidate for the treatment of mild-to-moderate psoriasis. The company hopes to file ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
